Qualigen Therapeutics ( NASDAQ: QLGN ) on Thursday said it has received written notice from Nasdaq, indicating the company’s continued non-compliance with the minimum bid price requirement. The company received a letter from Nasdaq notifying that, because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business days, it no longer complies with the minimum bid price requirement for continued listing.
Source: Press Release More on Qualigen Therapeutics Seeking Alpha’s Quant Rating on Qualigen Therapeutics Historical earnings data for Qualigen Therapeutics Financial information for Qualigen Therapeutics.
